Clinical trial
Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup…
NCT00134719 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00134719 |
|---|---|
| Title | Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines |
| Official title | A Multicentre Primary & Booster Vaccination Study of GSK Biologicals' Hib-MenCY-TT Conjugate Vaccine vs ActHIB® & MenC Conjugate Licensed Vaccine When Given According to the 2-4-6 Month Schedule to Healthy Infants With Booster Dose at 12 to 15 Months |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neisseria Meningitidis, Haemophilus Influenzae Type b |
| Intervention type | Biological |
| Interventions | MenHibrix (Hib-MenCY-TT), Infanrix® Penta, Prevenar®, ActHIB®, Meningitec®, M-M-R®II, Varivax®, PedvaxHIB® |
| Enrollment | 1,104 |
| Start date | Apr 11, 2005 |
| Primary completion | Jul 24, 2006 |
| Completion | Feb 21, 2007 |
| First posted | Aug 25, 2005 |
| Last update posted | Jul 19, 2018 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: